Table 1.
Non-compliance rates
| Group | Discontinuation due to non-availability | Discontinuation due to side effects |
|---|---|---|
| Topiramate (n=41) | 2 (4.9%) | 1 (2.4%) |
| Naltrexone (n=37) | 8 (21.6%) | 3 (8.1%) |
| Acamprosate (n=40) | 7 (17.5%) | 5 (12.5%) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.